MediPharm Labs (TSX:LABS) EBIT per Share : C$-0.03 (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs EBIT per Share?

MediPharm Labs's EBIT per Share for the three months ended in Dec. 2024 was C$-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was C$-0.03.

During the past 3 years, the average EBIT per Share Growth Rate was 46.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MediPharm Labs's EBIT per Share or its related term are showing as below:

TSX:LABS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 19.6 Med: 46.7 Max: 54.4
Current: 46.7

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of MediPharm Labs was 54.40% per year. The lowest was 19.60% per year. And the median was 46.70% per year.

TSX:LABS's 3-Year EBIT Growth Rate is ranked better than
87% of 823 companies
in the Drug Manufacturers industry
Industry Median: 8.3 vs TSX:LABS: 46.70

MediPharm Labs's EBIT for the three months ended in Dec. 2024 was C$-1.71 Mil.

MediPharm Labs EBIT per Share Historical Data

The historical data trend for MediPharm Labs's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs EBIT per Share Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.46

-0.18

-0.11

-0.04

-0.03

MediPharm Labs Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-

MediPharm Labs EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MediPharm Labs's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.118	/	407.993
=	-0.02

MediPharm Labs's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.705	/	411.831
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.03

MediPharm Labs (TSX:LABS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MediPharm Labs EBIT per Share Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MediPharm Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (TSX:LABS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MEDIF:USA MLZ:Germany

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.

Executives

Keith Strachan	Director
Gregory Edison Hunter	Senior Officer
David Pidduck	Director, Senior Officer
Bryan Howcroft	Director, Senior Officer
Patrick Mccutcheon	Director
Warren Everitt	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Etf Managers Trust	10% Security Holder
Christopher David Taves	Director
Sybil Taylor	Senior Officer
Braden Fenske	Senior Officer
David John Mayers	Senior Officer